Hemogenyx Pharmaceuticals PLC (HEMO) — Working Capital to Net Assets Ratio
Hemogenyx Pharmaceuticals PLC (HEMO) has a Working Capital to Net Assets ratio of 137.8% as of June 2025. Working capital of GBX-752.98K (current assets of GBX569.81K minus current liabilities of GBX1.32 Million) is measured against net assets of GBX-546.41K. A higher ratio indicates strong short-term liquidity financed by the equity base. See Hemogenyx Pharmaceuticals PLC (HEMO) net asset quality to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Hemogenyx Pharmaceuticals PLC Working Capital to Net Assets (2015–2024)
This chart shows how Hemogenyx Pharmaceuticals PLC's Working Capital to Net Assets ratio has evolved across 10 annual periods from 2015 to 2024. As of June 2025, the ratio stands at 137.8%, reflecting working capital of GBX-752.98K against net assets of GBX-546.41K GBX. Check Hemogenyx Pharmaceuticals PLC (HEMO) tangible net worth to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Hemogenyx Pharmaceuticals PLC (2015–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Hemogenyx Pharmaceuticals PLC from 2015 to 2024, covering 10 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see how much is Hemogenyx Pharmaceuticals PLC worth.
| Year | WC/NA Ratio | Working Capital (GBX) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -37.4% | GBX-319.61K | GBX853.49K | GBX839.05K | GBX1.16 Million | ▼ -92.0 pp |
| 2023 | 54.6% | GBX1.52 Million | GBX2.78 Million | GBX2.17 Million | GBX652.09K | ▼ -2.4 pp |
| 2022 | 56.9% | GBX1.85 Million | GBX3.24 Million | GBX2.59 Million | GBX748.41K | ▼ -26.2 pp |
| 2021 | 83.1% | GBX6.79 Million | GBX8.17 Million | GBX7.14 Million | GBX352.84K | ▲ +67.3 pp |
| 2020 | 15.8% | GBX138.40K | GBX875.68K | GBX1.92 Million | GBX1.78 Million | ▲ +122.6 pp |
| 2019 | -106.8% | GBX372.91K | GBX-349.04K | GBX554.48K | GBX181.57K | ▼ -282.5 pp |
| 2018 | 175.7% | GBX1.69 Million | GBX959.17K | GBX1.85 Million | GBX167.61K | ▲ +96.8 pp |
| 2017 | 78.9% | GBX1.68 Million | GBX2.13 Million | GBX1.95 Million | GBX263.69K | ▼ -21.1 pp |
| 2016 | 100.0% | GBX903.71K | GBX903.71K | GBX1.05 Million | GBX143.69K | ▲ +6.5 pp |
| 2015 | 93.5% | GBX72.73K | GBX77.82K | GBX89.01K | GBX16.28K | — |